Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ER positive + ESR1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	elacestrant Sensitive: A1 - Approval elacestrant Sensitive : A1	elacestrant Sensitive: A1 - Approval elacestrant Sensitive : A1
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ARV-471 Sensitive: C3 – Early Trials ARV-471 Sensitive : C3	ARV-471 Sensitive: C3 – Early Trials ARV-471 Sensitive : C3
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	DIACC3010 Sensitive: C3 – Early Trials DIACC3010 Sensitive : C3	DIACC3010 Sensitive: C3 – Early Trials DIACC3010 Sensitive : C3
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	AZD9833 Sensitive: C3 – Early Trials AZD9833 Sensitive : C3	AZD9833 Sensitive: C3 – Early Trials AZD9833 Sensitive : C3
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	GDC-0927 Sensitive: C3 – Early Trials GDC-0927 Sensitive : C3	GDC-0927 Sensitive: C3 – Early Trials GDC-0927 Sensitive : C3
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	inavolisib + GDC-9545 Sensitive: C3 – Early Trials inavolisib + GDC-9545 Sensitive : C3	inavolisib + GDC-9545 Sensitive: C3 – Early Trials inavolisib + GDC-9545 Sensitive : C3